The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus

Table 1

Change of biochemical index after metformin or canagliflozin treatment.

	Metformin				Canagliflozin				value^b
	Pretreatment	Posttreatment	%change	value^a	Pretreatment	Posttreatment	%change	value^a
Weight (kg)			0.04	0.363			-2.5	<0.001	0.233
SBP (mmHg)			-3.3	0.356			-3.7	0.138	0.902
DBP (mmHg)			-3.6	0.356			-4.5	0.116	0.837
HbA1c (%)			-15.6	0.001			-18.8	<0.001	0.319
ALT (U/L)			-20.6	0.045			-28.8	0.01	0.342
AST (U/L)			-2.9	0.779			-21.5	0.009	0.103
GGT (U/L)			-25.7	0.043			-20.2	0.001	0.574
ALP (U/L)			-9.4	0.02			-8.3	0.002	0.384
TBIL (μmol/L)			-6.6	0.257			-17.5	0.014	0.227
DBIL (μmol/L)			-1.9	0.751			-5.3	0.19	0.543
TBA (μmol/L)			9.1	0.49			10.0	0.299	0.840
GLU (mmol/L)			-20.7	0.007			-22.1	<0.001	0.773
C-peptide (ng/mL)			-21.6	0.067			-7.5	0.129	0.357
Insulin (mU/L)			-32.6	0.152			-15.2	0.208	0.259
K (mmol/L)			35.4	0.323			-0.5	0.746	0.220
Na (mmol/L)			0.03	0.946			-0.1	0.859	0.867
CL (mmol/L)			0.4	0.406			-2.6	0.336	0.361
Ca (mmol/L)			0.9	0.462			-0.8	0.175	0.155
P (mmol/l)			0.9	0.744			3.6	0.153	0.478
Mg (mmol/L)			-3.4	0.448			3.5	0.171	0.217
Cr (μmol/L)			5.2	0.035			2.3	0.249	0.409
BUN (mmol/L)			-7.9	0.079			8.0	0.048	0.042
UA (μmol/L)			7.4	0.048			-15.5	<0.001	0.012
Lipid profile
TG (mmol/L)			5.2	0.653			-8.3	0.662	0.079
TC (mmol/L)			-5.4	0.172			-3.8	0.151	0.740
HDL-c (mmol/L)			-1.6	0.577			9.1	0.005	0.024
LDL-c (mmol/L)			-4.6	0.210			-6.1	0.236	0.821
ANGPTL3 (ng/mL)			-3.5	0.579			-22.7	<0.001	0.015
ANGPTL4	—	—	—	—			-9.7	0.215	—
ApoA1	—	—	—	—			-0.5	0.726	—

^a value for the intragroup comparison (pre- vs. posttreatment values in metformin or canagliflozin group). ^b value for intergroup comparison (metformin vs. canagliflozin group in the changes from pre- to posttreatment).